Showing results (31-40 of 49) with videos related to
Sort By:
Pageof 5
Acta Dermato-Venereologica|February 16, 2022
Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe PsoriasisKim Papp, Carle Paul, C Elise Kleyn, et al.AIDS (London, England)|January 13, 2017
Impact of HIV infection and antiretroviral treatment on N-terminal prohormone of brain natriuretic peptide as surrogate of myocardial functionChristopher Schuster, Christina Binder, Robert Strassl, et al.Advances in Therapy|June 18, 2023
Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16Jacob P Thyssen, Marjolein de Bruin-Weller, Antonio Costanzo, et al.Journal of Proteome Research|May 15, 2012
A comparative proteomic study of human skin suction blister fluid from healthy individuals using immunodepletion and iTRAQ labelingAndré C Müller, Florian P Breitwieser, Heinz Fischer, et al.Acta Dermato-Venereologica|September 5, 2024
Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO)April W Armstrong, Elisabeth Riedl, Patrick M Brunner, et al.Advances in Therapy|November 9, 2024
Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO)Saakshi Khattri, Álvaro González-Cantero, Burhan Engin, et al.Rheumatology and Therapy|July 3, 2023
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic ArthritisBruce W Kirkham, Alexander Egeberg, Frank Behrens, et al.Advances in Therapy|December 14, 2022
Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World SettingCharles Lynde, Elisabeth Riedl, Julia-Tatjana Maul, et al.Expert Opinion on Drug Safety|September 5, 2024
Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studiesSergio Schwartzman, Luis Puig, Arnon D Cohen, et al.The Journal of Investigative Dermatology|January 26, 2018
The Reticulum-Associated Protein RTN1A Specifically Identifies Human Dendritic CellsMaria Gschwandtner, Philip Kienzl, Poojabahen Tajpara, et al.Pageof 5